Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Chinese Academy of Medical Sciences |
---|---|
Information provided by: | Chinese Academy of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT00699062 |
The distal lung contributes to asthmatic airway remodeling which is observed from early onset of the disease. Cysteinyl leukotrienes (CysLT) play important role in the pathogenesis of airway remodeling and antileukotrienes work to exert a certain degree of anti-inflammatory effect. The cysteinyl leukotriene antagonist Montelukast has been in vivo shown to significantly inhibit ovalbumin induced airway smooth muscle hyperplasia and subepithelial fibrosis in sensitized mice. This study aims to evaluate if Montelukast could reverse airway remodeling in asthma patients by a non-invasive approach-HRCT.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: leukotriene receptor antagonist (montelukast) Drug: placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Effect of Montelukast on the Airway Remodeling in Asthma Patients: Physiological-Radiological Correlation |
Estimated Enrollment: | 40 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | April 2011 |
Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
P: Placebo Comparator
The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and placebo for 6 months.
|
Drug: placebo
placebo, 10mg, QN, 6 months
|
T: Experimental
The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and montelukast for 6 months
|
Drug: leukotriene receptor antagonist (montelukast)
leukotriene receptor antagonist montelukast 10mg, QN, 6 months
|
Ages Eligible for Study: | 16 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jinming Gao, M.D., Ph.D. | 86-10-6529-5035 | gjinming@yahoo.com |
Contact: Lei Shu, M.D. | 86-21-6391-5522 ext 567 | shirleen_shu@merck.com |
China | |
Peking Union Medical College Hospital | |
Beijing, China, 100730 |
Principal Investigator: | Jinming Gao, M.D., Ph.D. | Peking Union Medical College Hospital |
Responsible Party: | Peking Union Medical College Hospital ( Jinming Gao ) |
Study ID Numbers: | JGao001, Merck-IISP001 |
Study First Received: | June 11, 2008 |
Last Updated: | June 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00699062 |
Health Authority: | China: Ethics Committee |
antileukotriene small airway airway remodeling HRCT |
Montelukast Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Hypersensitivity, Immediate Asthma Leukotriene Antagonists Respiratory Hypersensitivity |
Respiratory System Agents Immune System Diseases Bronchial Diseases Therapeutic Uses Hormone Antagonists |
Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents Pharmacologic Actions |